However, the development of S100 antibodies for cancer therapy is at its very beginning, and examples of other therapeutic antibodies showed that limited clinical efficacy, for example, due to lacking tumour tissue penetration, immune reactions, and antibody resistance [252], is an issue which might need to be overcome in the later stages of this process. The gene discussed is S100A1; the disease is neoplasm.